Medical device maker Glaukos posts smaller-than-expected loss in Q3 on strong demand in U.S.

Glaukos

29/10/2025 20:38

Overview

Glaukos Q3 2025 net sales grow 38% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q3 2025 also beats analyst expectations

Company raises 2025 net sales guidance, introduces preliminary 2026 guidance

Outlook

Glaukos raises 2025 net sales guidance to $490 mln-$495 mln

Glaukos introduces preliminary 2026 net sales guidance of $600 mln-$620 mln

Result Drivers

GLAUCOMA SALES - Record net sales in glaucoma segment, with U.S. sales increasing 57% yr/yr, driving overall growth

STRATEGIC EXECUTION - Strong momentum attributed to successful execution of strategic plans, per CEO Thomas Burns

PRODUCT PIPELINE - Advancement of novel, dropless platform technologies contributing to improved patient outcomes

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$133.50 mln
$122.50 mln (14 Analysts)
Q3 Adjusted loss per share
Beat
-$0.16
-$0.26 (15 Analysts)
Q3 Adjusted Net loss
Beat
-$9.20 mln
-$14.80 mln (13 Analysts)
Q3 Net loss
-$16.20 mln
Q3 Gross Margin
78%
Q3 Adjusted Gross Margin
84%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Glaukos Corp is $115.00, about 32.4% above its October 28 closing price of $77.79

Press Release: ID:nBwbRXfjza

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)